Welcome to our dedicated page for Biocardia news (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on Biocardia stock.
BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its recurring company updates center on the CardiAMP autologous cell therapy platform, CardiALLO allogeneic cell therapy programs, and device and software technologies used to deliver therapies to the heart, including the Helix transendocardial delivery catheter and Heart3D Fusion Imaging software.
News about BCDA commonly covers clinical results in ischemic heart failure with reduced ejection fraction, FDA and Japan PMDA regulatory interactions, patent protection for procedure-planning and navigation technology, and annual financial results. Company communications also address the role of Helix and related vascular navigation platforms in minimally invasive intramyocardial delivery of therapeutic and diagnostic agents.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioCardia, Inc. (Nasdaq: BCDA) announced the issuance of two significant patents that enhance its capabilities in cellular therapies for cardiovascular diseases. The U.S. Patent Office granted Patent Number 11,716,859 for a 'Multi-Directional Steerable Catheter' which will expire in 2035, supporting advanced catheter navigation and performance. Additionally, the Indian Patent Office issued Patent Number 424579 for 'Steerable Endoluminal Devices,' which will expire in late 2031, reflecting the robust design of BioCardia’s products used in over 10,000 patient treatments. These patents are expected to strengthen BioCardia's market position and protect its innovative therapeutic approaches.
BioCardia, Inc. (Nasdaq: BCDA) announced its 2022 financial results, reporting revenues of $1.4 million, a rise from $1.0 million in 2021, driven by collaborations and performance obligations. R&D expenses increased to $8.8 million, while SG&A costs decreased to $4.4 million. The net loss narrowed to $11.9 million, down from $12.6 million in the previous year. Notably, BioCardia is advancing four clinical studies in novel cell therapies for heart failure and pulmonary conditions, with potential catalysts for growth in 2023. The company ended 2022 with $7.4 million in cash, providing operational runway through Q3 2023.
BioCardia, Inc. (NASDAQ: BCDA) announced it will report its financial results for the year ended December 31, 2022, during a conference call on March 29, 2023, at 4:30 PM ET. The call will include a corporate update followed by a Q&A session. Interested participants can register for the call through a provided link and will receive their dial-in number upon registration. The conference call will also be accessible via a live webcast. A replay of the call will be available shortly after, lasting until June 29, 2023. BioCardia focuses on developing biotherapeutics for cardiovascular and pulmonary diseases, leveraging two main platforms for its product candidates.